LABU a 3X leveraged ETF of biotechnology stocks LONG
LABU on a 240-minute chart has been in a trend up gaining 100% in 3 months. Both the fast and
slow ( green and red) are above the 50 level. Biotechnology is expected to be a hot subsector
this year as healthcare recovered further from the COVID pandemic anything from startups to
big pharma- from vaccines to new drugs for diabetes, liver disease and obesity. Leveraged
funds have time decay from the leveraging and management fees and are meant to be for
short-term trading. Nonetheless, 100% in 3 months is an excellent return. I add to my position
when I see a pullback on the 15-30 minute chart. If price rises more than 2% in a day I may
take 1-2 shares off the position to realize some profit and recycle ( compound) into the next
buy. According to those that follow sectors, LABU should outperform this year.
slow ( green and red) are above the 50 level. Biotechnology is expected to be a hot subsector
this year as healthcare recovered further from the COVID pandemic anything from startups to
big pharma- from vaccines to new drugs for diabetes, liver disease and obesity. Leveraged
funds have time decay from the leveraging and management fees and are meant to be for
short-term trading. Nonetheless, 100% in 3 months is an excellent return. I add to my position
when I see a pullback on the 15-30 minute chart. If price rises more than 2% in a day I may
take 1-2 shares off the position to realize some profit and recycle ( compound) into the next
buy. According to those that follow sectors, LABU should outperform this year.
Zlecenie aktywne
Not unexpectedly LABU had a surge, 10% of the position closed to buy a single call option contract for LLY and another for NVAX, and another for MRNA. The latter heavily beat on the earnings report. Will deploy fresh capital into LABU upona dip down into the support of the liquidity-adjusted moving average cloud. Rinse
and repeat.
Wyłączenie odpowiedzialności
Informacje i publikacje przygotowane przez TradingView lub jego użytkowników, prezentowane na tej stronie, nie stanowią rekomendacji ani porad handlowych, inwestycyjnych i finansowych i nie powinny być w ten sposób traktowane ani wykorzystywane. Więcej informacji na ten temat znajdziesz w naszym Regulaminie.
Wyłączenie odpowiedzialności
Informacje i publikacje przygotowane przez TradingView lub jego użytkowników, prezentowane na tej stronie, nie stanowią rekomendacji ani porad handlowych, inwestycyjnych i finansowych i nie powinny być w ten sposób traktowane ani wykorzystywane. Więcej informacji na ten temat znajdziesz w naszym Regulaminie.